Three-drug combination enhanced lung function and decreased symptoms in cystic fibrosis (CF) patients who have the most common genetic mutation for the disease, according to a phase three clinical ...

The next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659–tezacaftor–ivacaftor), was developed to ...

Sildenafil is an orally active selective type 5 phosphodiesterase (PDE) inhibitor, and has proven to be an effective agent for the treatment of male ED. Sildenafil inhibits the breakdown of ...